Trial Profile
A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Subjects With Myelodysplastic Syndromes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.